Hardman & Co Research on Tissue Regenix (TRX): Maiden pre-tax profit   TRX is focused on the development and commercialisation of two proprietary processing technologies for the repair of soft tissue (dCELL®) and bone (BioRinse®). It has a broad portfolio of products used in biosurgery, orthopaedics and dental markets. Investment in tissue  [ … ]

Hardman & Co Research on Tissue Regenix (TRX): Maiden pre-tax profit   TRX is focused on the development and commercialisation of two proprietary processing technologies for the repair of soft tissue (dCELL®) and bone (BioRinse®). It has a broad portfolio of products used in biosurgery, orthopaedics and dental markets. Investment in tissue  [ … ]

Hardman & Co Insight: Survival of the UK life sciences sector   For two years running, the Hardman & Co Healthcare index has declined, underperforming both the FTSE 100 and the FTSE All-Share indices. This is quite unusual for healthcare stocks. Apart from the general economic influences, which have made institutions more risk-averse, the [ … ]

Hardman & Co Research on Tissue Regenix (TRX): Six consecutive periods of >20% growth   TRX is focused on the development and commercialisation of two proprietary processing technologies for the repair of soft tissue (dCELL®) and bone (BioRinse®). It has a broad portfolio of products used in biosurgery, orthopaedics and dental markets. I [ … ]